



ProAir[®] HFA (albuterol) – First-time generic

- On February 25, 2020, [Perrigo launched](#) an AB-rated generic version of Teva Respiratory's [ProAir HFA \(albuterol\)](#) inhalation aerosol.
 - Limited quantities of Perrigo's generic ProAir HFA were immediately launched.
 - A steady supply of Perrigo's generic ProAir HFA will be available by the fourth quarter of 2020.
 - Teva also launched an authorized brand alternative (ABA) of ProAir HFA in January 2019.
- ProAir HFA is approved for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and prevention of exercise-induced bronchospasm in patients aged 4 years and older.
- Albuterol inhalation aerosol is also available as an ABA by [Prasco](#) and brand [Ventolin[®] HFA](#), an ABA by [Par](#) and brand [Proventil[®] HFA](#), and brand inhalation powders [ProAir Respiclick[®]](#) and [ProAir Digihaler[™]](#).
 - All these forms of albuterol inhalation carry the same indications as ProAir HFA.
- According to IQVIA, ProAir HFA had sales for the previous 12 months of approximately \$1.4 billion in the U.S.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.